European Primary Care Cardiovascular Society
Attainment of 2016 guideline-recommended risk-based LDL-c goal was 54% and for 2019 risk-based LDL-c goal this was 33% in patients on lipid-lowering therapy in primary and secondary settings.
ESC 2020 Evolocumab, in addition to standard lipid-lowering therapies, resulted in a placebo-corrected difference of 38.3% for LDL-c after 24 weeks in pediatric HeFH patients.
Treatment with the PCSK9 inhibitor evolocumab reduced a composite of CV events compared to placebo in ASCVD patients with and without metabolic syndrome in a similar degree.
This systematic review and meta-analysis of 43 studies showed that the prescription prevalence in women was lower for aspirin, statins, and ACE inhibitors, but higher for diuretics, compared to men.
As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.
Total (first and subsequent) vascular events among patients with recent stroke or transient ischemic attack were reduced, as shown in a post-hoc analysis of the SPARCL trial.
ACC 2020 Dirk Blom discusses the design and outcomes of the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.
ACC 2020 The ODYSSEY HoFH trial demonstrated that treatment with alirocumab reduced LDL-c in HoFH patients compared to placebo, and alirocumab was found to be well tolerated and safe.
High intake of sugar-sweetened beverages was associated with adverse changes in HDL-c and triglyceride, along with higher incidence of dyslipidemias related to low HDL-c and high triglyceride.
Adults who started primary CV preventive pharmacotherapy showed higher BMI and more inactivity, but reduced smoking and alcohol consumption after about 4 years than those not taking drugs.
Data of US postmenopausal women with normal BMI show that trunk fat and higher leg fat have opposing associations with CVD risk, while total body fat was not significantly related to CVD risk.
ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.
